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OBJECTIVES The purpose of this study was to assess the impact of body mass index (BMI) on the short-
and long-term outcomes after percutaneous coronary intervention (PCI).
BACKGROUND Obesity is associated with advanced coronary artery disease (CAD). However, the relation
between BMI and outcome after PCI remains controversial.
METHODS We studied 9,633 consecutive patients who underwent PCI between January 1994 and
December 1999. Patients were divided into three groups according to BMI: normal, BMI
between 18.5 and 24.9 (n  1,923); overweight, BMI between 25 and 30 (n  4,813); and
obese, BMI 30 (n  2,897).
RESULTS Obese patients were significantly younger and had consistently worse baseline clinical
characteristics than normal or overweight patients, with a higher incidence of hypertension,
diabetes, hypercholesterolemia and smoking history (p  0.0001). Despite similar angio-
graphic success rates among the three groups, normal BMI patients had a higher incidence
of major in-hospital complications, including cardiac death (p  0.001). At one-year
follow-up, overall mortality rates were significantly higher for normal BMI patients compared
with overweight or obese patients (p  0.0001). Myocardial infarction and revascularization
rates did not differ among the three groups. By multivariate Cox regression analysis, diabetes,
hypertension, age, BMI and left ventricular function were independent predictors of
long-term mortality.
CONCLUSIONS In patients with known CAD who undergo PCI, very lean patients (BMI 18.5) and those
with BMI within the normal range are at the highest risk for in-hospital complications and
cardiac death and for increased one-year mortality. (J Am Coll Cardiol 2002;39:578–84)
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Excess body fat is an increasingly prevalent metabolic
disorder affecting both the U.S. population and several
countries in the developing world. More than 50% of
Americans are overweight, with 20% classified as obese by
the National Institutes of Health body weight guidelines
(1). Diets high in fat and calories and a sedentary lifestyle
with reduced physical activity are usually blamed for this
increase in the prevalence of obesity (2,3).
Obesity is considered a serious independent risk factor for
coronary heart disease, on par with cigarette smoking,
physical inactivity and elevated blood cholesterol levels (4).
Long-term longitudinal studies have also shown that obe-
sity is associated with excess cardiovascular morbidity and
mortality (5,6). However, there is limited data on the effect
of obesity on percutaneous coronary intervention (PCI)
success. An early study in the pre-stent era, has shown a
correlation between in-hospital mortality after PCI in both
underweight and very obese patients (7). While there is a
common clinical perception that markedly obese patients
have a higher short- and long-term risk after PCI (e.g.,
access site bleeding and restenosis, respectively), there is no
contemporary data assessing the effect of body mass index
(BMI) on short- and long-term outcome after PCI in the
modern interventional era.
METHODS
Patients. Using our comprehensive interventional data-
base, whereby charts from patients undergoing coronary
intervention are reviewed by dedicated, independent re-
search personnel unaware of the objectives or purpose of the
study, we identified a total of 9,633 patients who underwent
PCI between January 1994 and December 1999. Clinical
follow-up was performed by either telephone contact or
office visit at 6 and 12 months. The occurrence of major late
clinical events was recorded including death, Q-wave myo-
cardial infarction (MI) and revascularization procedures,
whether percutaneous or surgical. All events were source
documented and adjudicated.
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Clinical definitions. The presence of obesity was assessed
using BMI, which was defined as weight in kilograms
divided by height in meters squared (kg/m2). A BMI24.9
was considered normal range (non-overweight and non-
obese), a BMI between 25 and 30 was considered over-
weight and a BMI 30 was considered obese (8,9). For
one-year mortality, BMI was further divided based on
cut-off points proposed by the World Health Organization
(10,11). Procedural success was defined as the absence of
death, emergency coronary artery bypass grafting or Q-wave
MI (presence of new pathological Q waves associated with
an elevation of cardiac enzyme at least two times the upper
normal value). Non–Q-wave MI after PCI was defined as a
creatinine kinase-MB enzyme elevation at least three times
the upper normal value without new Q waves. Major
bleeding was defined as a reduction in hemoglobin 5 g/dl
(or 15% in hematocrit), any intracranial bleeding or the
need for 2 U of blood transfusion. Renal function dete-
rioration was defined as an increase in serum creatinine
levels 25% or the need for in-hospital dialysis. Vascular
complications were defined as the presence of a large
hematoma, retroperitoneal bleeding or the need for surgical
repair. Hypercholesterolemia was defined as a serum cho-
lesterol 240 mg/dl.
Procedure. All patients underwent PCI according to cur-
rent clinical guidelines with conventional steerable guide-
wire systems (12). The operator selected interventional
devices at the time of the procedure. All patients received
aspirin 325 mg daily at least 24 h before the procedure and
continued indefinitely afterwards. Patients who underwent
stenting were treated concomitantly with an additional
antiplatelet agent: either ticlopidine 250 mg twice daily or
clopidogrel 75 mg daily for four weeks per the routine
protocol. Weight-adjusted heparin dosage was administered
during the procedure in order to maintain an activated
clotting time 250 s to 300 s and was routinely discontinued
at the end of the procedure. Of all patients, 5% were
treated with glycoprotein IIb/IIIa inhibitors.
Angiographic analysis. An independent angiographic core
laboratory, blinded to the clinical data and the purpose of
this study, performed qualitative and quantitative coronary
angiographic analysis. The analysis was done on end-
diastolic cine frames demonstrating the stenosis in its more
severe and nonforeshortening projection; using a computer-
assisted, automated edge detection algorithm, quantitative
coronary angiographic analysis was performed using the
CMS-GFT system (Medis, Leiden, the Netherlands) and
the CASS system (Maastricht, the Netherlands) using
standard morphologic criteria (13). The contrast-filled cath-
eter was used as the calibration standard, and a three-reader
consensus was routinely employed.
Statistical analysis. Continuous variables are expressed as
mean  1 SD and categorical variables as percentages.
Comparisons among the three groups were performed by
analysis of variance for independent samples and the chi-
square test for comparison of categorical values. Cox mul-
tivariate analysis regression analysis was used to model
independent predictors of late mortality. Variables included
in the model were age, gender, diabetes, hypertension,
previous PCI, smoking, saphenous vein graft intervention,
left ventricular ejection fraction (LVEF) and BMI. Statis-
tical analysis was performed with SAS software (SAS
Institute, Cary, North Carolina). A p value 0.05 was
considered significant.
Table 1. Clinical Characteristics
Normal BMI
(n  1,923)
Overweight
(n  4,813)
Obese
(n  2,897) p Value
Age (yrs) 68  12 64  11 61  11  0.0001
Women (%) 40.3 25.6 34.9  0.0001
Unstable angina (%) 30.0 31.8 31.1 0.21
Acute MI (%) 2.9 2.5 3.0 0.20
Prior MI (%) 52.2 52.1 50.9 0.45
Prior CABG (%) 39.9 41.6 35.3  0.0001
Prior PTCA (%) 43.7 50.6 48.8  0.0001
Hypertension (%) 55.6 63.1 72.3  0.0001
Diabetes mellitus (%) 17.4 25.5 38.0  0.0001
Insulin treated (%) 7.3 10.8 19.2  0.0001
Oral hypoglycemic (%) 10.1 14.6 18.8  0.0001
Family history (%) 56.2 60.3 63.1  0.0001
Hypercholesterolemia (%) 63.1 71.3 73.6  0.0001
Smoking history (%) 54.3 57.1 59.2 0.0004
BMI 22  2 27  2 34  5  0.0001
BMI  body mass index; CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty.
Abbreviations and Acronyms
BMI  body mass index
CI  confidence interval
LVEF  left ventricular ejection fraction
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous coronary intervention
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RESULTS
Data on 9,633 consecutive patients who underwent PCI was
available for complete analysis. Half of the patients (50%)
were overweight, and 80% were either overweight (n 
4,813) or obese (n  2,897), with only 20% having normal
BMI (n 1,923). The baseline clinical characteristics of the
three groups differed significantly as shown in Table 1.
Obese patients were younger and had more risk factors for
coronary artery disease (CAD) than overweight or normal
BMI patients; they had higher rates of hypertension, dia-
betes mellitus, hypercholesterolemia and smoking history.
All of these differences were highly significant. Angio-
graphic characteristics are shown in Table 2. There was a
higher incidence of saphenous vein grafts treated in the
normal and overweight BMI groups and also a higher rate
of total occlusions in the normal and obese groups. Vessel
dimensions were very similar among the three groups
(Table 2). Device use was also similar among the three
groups, 46% (range: 42% to 47%, p  0.26) of the patients
underwent stenting and 26% (range: 27% to 29%, p 0.31)
underwent lesion modification by athero-ablative devices. A
total of 19% of normal BMI and overweight patients
underwent rotational atherectomy, compared with 26% in
the obese group (p  0.002). Excimer laser angioplasty use
was similar among the three groups, 8% (range: 6% to 9%,
p  0.10).
In-hospital clinical outcome. Table 3 summarizes the
short-term clinical outcome. Despite similar procedural and
angiographic success rates in all three groups, normal BMI
was associated with significantly higher rates of periproce-
Table 2. Angiographic Characteristics (Lesion-Based)
Normal BMI
(n  4,840)
Overweight
(n  12,266)
Obese
(n  7,149) p Value
Target vessel
Left main (%) 3.6 4.0 4.1 0.51
Left anterior descending (%) 31.1 30.1 29.9 0.46
Left circumflex (%) 22.0 23.2 28.9 0.006
Right coronary (%) 27.7 27.6 31.4 0.24
Saphenous vein graft (%) 15.6 15.1 5.7  0.0001
In-stent restenosis (%) 9.6 10.9 9.9 0.05
Total occlusion (%) 13.8 12.7 15.7 0.02
Thrombus (%) 5.9 6.7 5.7 0.39
Lesion length 20 mm (%) 13.7 11.6 14.2 0.07
Lesion type B or C (%) 80.2 81.3 80.7 0.74
Ejection fraction (%) 44  14 46  13 48  12  0.0001
Preprocedural
Reference vessel diameter (mm) 2.92  0.96 2.95  0.87 2.98  0.87 0.20
Diameter stenosis (%) 62  21 63  21 64  19 0.09
Minimal lumen diameter (mm) 1.06  0.74 1.07  0.69 1.06  0.69 0.88
Postprocedural
Diameter stenosis (%) 14  19 14  19 14  19 0.88
Minimal lumen diameter (mm) 2.61  1.04 2.60  0.94 2.63  0.92 0.64
BMI  body mass index.
Table 3. In-Hospital Outcome
Normal BMI
(n  1,923)
Overweight
(n  4,813)
Obese
(n  2,897) p Value
Procedural success (%) 97.3 97.4 97.6 0.74
Clinical success (%) 93.8 94.2 95.0 0.09
Pulmonary edema (%) 4.0 2.8 2.6 0.002
Hypotension (%) 4.8 3.2 2.9  0.0001
Renal insufficiency (%) 6.6 4.8 5.2 0.005
Death (%) 1.3 1.0 0.7 0.06
Cardiac death (%) 1.0 0.7 0.4 0.001
Myocardial infarction (%) 14.8 14.7 13.7 0.41
Q-wave (%) 0.4 0.4 0.3 0.79
Non–Q-wave (%) 21.4 20.2 19.4 0.19
Emergency CABG (%) 1.6 1.6 1.7 0.99
Vascular complications (%) 5.9 3.6 3.9  0.0001
Major bleeding (%) 4.5 3.5 3.1 0.01
BMI  body mass index; CABG  coronary artery bypass grafting.
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dural complications and of cardiac-related death. Of note,
the normal BMI patients also had a higher rate of major
bleeding (p  0.01) and major vascular complications (p 
0.001) than the overweight and obese patients. Cardiac
mortality was higher in the normal BMI patients, and
overall mortality tended to be higher in patients with normal
BMI (p  0.055).
Long-term outcome. One-year clinical outcomes for all
three groups are shown in Table 4 and in Figure 1. Overall
one-year mortality rates and cardiac-related deaths were
significantly higher in patients with normal BMI (p 
0.0001) (Fig. 2). Because age is known to be such a strong
predictor of mortality, analysis by age groups showed that
one-year mortality rates were higher in patients with normal
BMI for all age groups, except for patients 50 years old
(Fig. 3). In order to assess the contribution of gender and
BMI to overall mortality, we further distributed the BMI
according to guidelines from the International Obesity Task
Force by gender (12). Peak mortality rates were seen in
female patients with BMI 18.5 and in male patients with
a BMI 20 (Fig. 4). When patients who had never smoked
were analyzed separately and compared with former and
current smokers, the results did not change, and very lean
patients still had the highest mortality rates. For patients
who had never smoked, mortality rates were lowest at the
same BMI as in the general population. There was no
significant difference in MI and revascularization rates at
one-year follow-up among the three groups. Multivariate
regression analysis showed that diabetes (odds ratio [OR]
1.97, 95% confidence interval [CI]  1.61 to 2.41, p 
0.0001), hypertension (OR  1.46, 95% CI  1.16 to 1.83,
p  0.001), age (OR  1.04, 95% CI  1.03 to 1.06, p 
Table 4. 12-Month Outcome
Normal BMI
(n  1,923)
Overweight
(n  4,813)
Obese
(n  2,897) p Value
MACE (%) 25.8 23.1 22.7 0.02
Death (%) 10.6 5.7 4.9  0.0001
Cardiac death (%) 4.8 3.3 2.5  0.0001
Myocardial infarction (%) 7.4 7.0 6.7 0.66
Q-wave (%) 1.5 1.2 0.8 0.10
Non–Q-wave (%) 6.2 6.0 6.1 0.92
TLR (%) 17.4 18.6 19.0 0.37
TVR (%) 20.2 22.0 22.4 0.16
BMI  body mass index; MACE  major adverse cardiac events (death, myocardial infarction and target lesion
revascularization); TLR  target lesion revascularization; TVR  target vessel revascularization.
Figure 1. Kaplan-Meier curves illustrating death-free survival curves at 12 months follow-up. BMI  body mass index.
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0.0001), BMI (OR  0.96, 95% CI  0.94 to 0.98, p 
0.0003) and LVEF (OR 0.05, 95% CI 0.79 to 0.85, p
0001) were independent predictors of long-term mortality.
DISCUSSION
In this study, we analyzed the impact of BMI on the
in-hospital and one-year outcome of a large cohort of
patients who underwent PCI. The working hypothesis was
that overweight and obese patients have a worse in-hospital
and long-term outcome after PCI. Contrary to our suppo-
sition, we found that normal BMI patients (male or female,
smokers or nonsmokers) had higher in-hospital and one-
year mortality rates when compared with overweight or
obese patients, despite a better baseline clinical profile.
Postprocedural complications, such as hypotension, pulmo-
nary edema, renal function deterioration, major bleeding,
access site hematoma, vascular complications and overall
mortality rates were surprisingly higher in lean patients
compared with overweight or obese patients. Furthermore,
mortality rates were considerably higher for very lean female
patients (18.5 kg/m2) compared with very lean male
patients. At one-year follow-up, overall mortality rates were
significantly higher in normal BMI patients, and cardiac-
related deaths accounted for half of all deaths in all three
groups.
Mechanism. The mechanism by which normal BMI pa-
tients had an excess of these complications is not clear but
could be related to the excessive anticoagulation in thin
patients or the presence of severe, noncardiovascular, un-
derlying diseases in very lean patients, as shown in previous
trials (14,15). Overall in-hospital mortality rates were low,
but there was an increased mortality in normal BMI
patients; cardiac-and noncardiac-related deaths were signif-
icantly more frequent in normal BMI patients. When
gender and smoking status were analyzed separately, higher
mortality rates persisted in low and normal BMI patients at
one-year follow-up.
Previous studies. These results are similar to those re-
ported by Ellis et al. (7) from the pre-stent era, in which
patients with low-normal BMI had worse in-hospital out-
come after percutaneous balloon angioplasty than normal
BMI patients. Such a trend was also seen in the British
Regional Heart study, in which there was a U-shaped
relation between BMI and mortality in middle-aged British
men, with the highest mortality rates seen in very lean men
(BMI 20) (14). The very high mortality rate in this group
was attributed to noncardiovascular causes, particularly di-
gestive tract cancer, lung cancer and respiratory diseases,
which could be associated with cigarette smoking (14,15).
The lean population is often a combination of patients who
have lost weight due to underlying debilitating diseases and
Figure 2. One-year overall and cardiac mortality rates among all patients according to body mass index (BMI).
Figure 3. One-year mortality rates from all causes adjusted for age and
body mass index (BMI) for all patients.
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smokers (who have a tendency to weigh less and have higher
mortality rates compared with nonsmokers) (16–18). Mor-
tality in these patients is usually related to cancer and
“other” occult diseases rather than leanness per se. In this
study, we also observed a poor outcome in the leanest
patients. While it is possible that the poor outcome was due
to other, noncardiac causes, low BMI was also related to
cardiac-related death and was observed in smokers and
nonsmokers alike.
It is important to take into account that most studies
assessing the relationship between obesity and outcomes
were prospective and performed in a large number of
healthy subjects who were usually free of diagnosed chronic
diseases and followed for a prolonged period of time. The
consequence of excess body weight on mortality is delayed
and may not be seen in short-term studies such as this one
(19,20). The effects of obesity increase with the duration of
follow-up and the age of the subjects, with increased
mortality in the very lean patients during the first years of
follow-up and increased mortality in the obese patients in
subsequent years (20–24).
Study limitations. This was a retrospective analysis and,
therefore, the results and conclusions are subject to the
limitations inherent in all such reports. A BMI-based
definition describes weight related to height and fails to take
body fat distribution into account, which may be a better
predictor for cardiovascular risk (25). Although there were
significant differences in the baseline clinical characteristics
among the three BMI groups, the known cardiovascular risk
factors were not more common in obese patients and,
therefore, cannot account for their lower mortality rates.
The present study does not take into account recent weight
loss and shifts in body weight, which may be associated with
significant increases in risk, nor does it provide follow-up
for 1 year. Patients with cancer or other serious comor-
bidities were not excluded from the analysis.
Conclusions. This study suggests the following: 1) in
patients with known CAD who undergo PCI, very lean
patients and patients with BMI within the normal range are
at the highest risk for in-hospital major complications,
including cardiac death; 2) the increased mortality in these
patients is also seen at one-year follow-up, with a concom-
itant increase in major adverse cardiac events rates; 3) very
lean female patients in this group seem to be at the highest
risk; 4) the relatively short follow-up period (one year) does
not allow for the assessment of long-term adverse effects of
obesity; and 5) obese patients who undergo PCI are, on
average, approximately seven years younger than their nor-
mal BMI counterparts.
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